Featured Company News – Cellectis Announced the IPO of its Subsidiary Calyxt

Research Desk Line-up: Burcon Nutrascience Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cellectis S.A. (NASDAQ: CLLS), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=CLLS. The Biopharma Company announced on July 10, 2017, that its wholly owned subsidiary, Calyxt, Inc., has started the process for an IPO (initial public offering) and filed relevant papers with the US Securities and Exchange Commission (SEC). Calyxt is engaged in the business of gene editing in agriculture. After the completion of the IPO, Cellectis plans to continue owning a majority stake in Calyxt. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Burcon Nutrascience Corporation (NASDAQ: BUR) for due-diligence and potential coverage as the Company reported on June 21, 2017, its financial results for the year which ended on March 31, 2017. Tune into our site to register for a free membership, and be among the early birds that get our report on Burcon Nutrascience when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on CLLS; also brushing on BUR. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=CLLS

http://protraderdaily.com/optin/?symbol=BUR

Details of the IPO

The IPO is for 6,060,606 Calyxt’s shares and the estimated price of each share would be in the range of $15 to $18. Based on the median price of the shares in this price band, the total value of the IPO would be approximately $100 million. Calyxt plans to list its shares at the NASDAQ stock exchange and would trade under the ticker “CLXT”.

Calyxt plans to offer its underwriters the option of purchasing up to 909,091 extra shares of the Company so that the underwriters can handle over-allotments if any.

The participation in the IPO is only through a prospectus which can be availed from the offices of Citigroup, Jefferies LLC, and Wells Fargo Securities. Citigroup, Jefferies, and Wells Fargo Securities are the joint book-running managers and BMO Capital Markets and Ladenburg Thalmann are the co-managers for the proposed IPO of Calyxt.

About Cellectis

Cellectis was founded in 1999 and is a clinical-stage biopharmaceutical Company that harnesses the immune system to target and eradicate cancers. Cellectis uses gene editing to create cost-effective, “off-the-shelf” (allogeneic) products (UCART) from healthy donors that can be immediately available for patients across all geographies. For those patients without enough T-cells for autologousCAR T therapy, Cellectis has the technology to create T-cells based on patients’ own T-cells.

The Company has over 17 years of expertise in gene editing technology and is based on its proprietary TALEN® technology and pioneering electroporation system PulseAgile. The Company uses these proprietary systems to develop a new generation of immunotherapy product candidates that have additional safety and efficacy features that prevent them from attacking healthy tissues and equip them to resist mechanisms that inhibit immune system activity. Cellectis’ allogeneic cells remain strong compared to autologous treatments that use the patient’s own T-cells which get progressively weaker with each round of chemotherapy.

About Calyxt

Calyxt was founded in 2010 and is headquartered in St. Paul, Minnesota. The Company uses the gene-editing technology and technical expertise developed by Cellectis and the University of Minnesota to create new varieties of crops to produce healthier food products. Calyxt is developing or creating specialty food ingredients, such as healthier oils and high fiber wheat, and food crops with desirable traits such as herbicide tolerance.

Last Close Stock Review

On Tuesday, July 11, 2017, the stock closed the trading session at $25.65, slipping 1.65% from its previous closing price of $26.08. A total volume of 50.38 thousand shares has exchanged hands. Cellectis’ stock price soared 9.20% in the last three months, 35.36% in the past six months. Furthermore, since the start of the year, shares of the Company have skyrocketed 51.33%. At Tuesday’s closing price, the stock’s net capitalization stands at $888.26 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467885